StockMacro
Menu

Charles River Laboratories International

$314.32 +101% in 6 monthsMarket cap $15.1B

CRL on XNYS, Health Care, Charles River Laboratories International, Inc., job postings

Measures activity, not value. Not investment advice.

Shares up 94% in 12 months while quarterly revenue fell 2.2% and layoff notices covered 73 workers.

  • BadShort interest 6.2% of shares, up 5.4% from two weeks earlier
  • WatchCompanies with recent layoff notices beat sector by median 11.0 points

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 26 Sep 2026

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provide in vitro (nonanimal) testing products, biologics testing services, and avian vaccine services.

Industry
Services-commercial physical & biological research (Health Care)
Employees
19,700
Website
criver.com
Listed
NYSE, US
Last results
4 Nov 2026
Next results
expected around 12 Jan 2027 (an estimate: a year ago it reported on 13 Jan 2026)
Revenue and net income per quarter. Quarter to 26 Sep 2026: revenue $982.7M, net income $333.1M.
Quarter to 25 Dec 2021: revenue $905.0M, net income $137.6MQuarter to 25 Dec 2021: revenue $905.0M, net income $137.6MQuarter to 26 Mar 2022: revenue $913.9M, net income $93.0MQuarter to 26 Mar 2022: revenue $913.9M, net income $93.0MQuarter to 25 Jun 2022: revenue $973.1M, net income $109.3MQuarter to 25 Jun 2022: revenue $973.1M, net income $109.3MQuarter to 24 Sep 2022: revenue $989.2M, net income $96.5MQuarter to 24 Sep 2022: revenue $989.2M, net income $96.5MQuarter to 31 Dec 2022: revenue $1.1B, net income $187.4MQuarter to 31 Dec 2022: revenue $1.1B, net income $187.4MQuarter to 1 Apr 2023: revenue $1.0B, net income $103.1MQuarter to 1 Apr 2023: revenue $1.0B, net income $103.1MQuarter to 1 Jul 2023: revenue $1.1B, net income $97.0MQuarter to 1 Jul 2023: revenue $1.1B, net income $97.0MQuarter to 30 Sep 2023: revenue $1.0B, net income $87.4MQuarter to 30 Sep 2023: revenue $1.0B, net income $87.4MQuarter to 30 Dec 2023: revenue $1.0B, net income $187.1MQuarter to 30 Dec 2023: revenue $1.0B, net income $187.1MQuarter to 30 Mar 2024: revenue $1.0B, net income $73.0MQuarter to 30 Mar 2024: revenue $1.0B, net income $73.0MQuarter to 29 Jun 2024: revenue $1.0B, net income $94.1MQuarter to 29 Jun 2024: revenue $1.0B, net income $94.1MQuarter to 28 Sep 2024: revenue $1.0B, net income $69.7MQuarter to 28 Sep 2024: revenue $1.0B, net income $69.7MQuarter to 28 Dec 2024: revenue $1.0B, net income -$214.5MQuarter to 28 Dec 2024: revenue $1.0B, net income -$214.5MQuarter to 29 Mar 2025: revenue $984.2M, net income $25.5MQuarter to 29 Mar 2025: revenue $984.2M, net income $25.5MQuarter to 28 Jun 2025: revenue $1.0B, net income $52.3MQuarter to 28 Jun 2025: revenue $1.0B, net income $52.3MQuarter to 27 Sep 2025: revenue $1.0B, net income $54.4MQuarter to 27 Sep 2025: revenue $1.0B, net income $54.4MQuarter to 27 Dec 2025: revenue $994.2M, net income -$276.6MQuarter to 27 Dec 2025: revenue $994.2M, net income -$276.6MQuarter to 28 Mar 2026: revenue $995.8M, net income -$14.8MQuarter to 28 Mar 2026: revenue $995.8M, net income -$14.8MQuarter to 27 Jun 2026: revenue $1.0B, net income -$1.5MQuarter to 27 Jun 2026: revenue $1.0B, net income -$1.5MQuarter to 26 Sep 2026: revenue $982.7M, net income $333.1MQuarter to 26 Sep 2026: revenue $982.7M, net income $333.1M
25 Dec 2021RevenueNet incomeNet losstallest bar $1.1B26 Sep 2026
See the numbers
Quarter toRevenueNet income
26 Sep 2026$982.7M$333.1M
27 Jun 2026$1.0B-$1.5M
28 Mar 2026$995.8M-$14.8M
27 Dec 2025$994.2M-$276.6M
27 Sep 2025$1.0B$54.4M
28 Jun 2025$1.0B$52.3M
29 Mar 2025$984.2M$25.5M
28 Dec 2024$1.0B-$214.5M
28 Sep 2024$1.0B$69.7M
29 Jun 2024$1.0B$94.1M
30 Mar 2024$1.0B$73.0M
30 Dec 2023$1.0B$187.1M
30 Sep 2023$1.0B$87.4M
1 Jul 2023$1.1B$97.0M
1 Apr 2023$1.0B$103.1M
31 Dec 2022$1.1B$187.4M
24 Sep 2022$989.2M$96.5M
25 Jun 2022$973.1M$109.3M
26 Mar 2022$913.9M$93.0M
25 Dec 2021$905.0M$137.6M
Fundamentals, 12 months to 26 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $4.0B $4.0B
Revenue growthRevenue of the last 12 months compared with the 12 months before. -1.2% +3.4%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $40.2M -$82.3M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $0.97 -$1.51
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 63.5%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 4.0% 3.5% 4.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 1.0% -2.0% 1.0%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 1.2% -16.5%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $399.6M $543.7M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $200.4M $207.1M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $2.4B $2.2B
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). $2.2B $2.0B
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.76 0.00
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $67.35
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 375 57.9
P/SPrice to sales: market cap divided by revenue of the last 12 months. 3.8 4.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 4.4 4.4
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 4.7 4.4

Latest = 12 months to 26 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Charles River Laboratories InternationalCRL (this company) $15.1B3753.8-1.2%1.0%
MedpaceMEDP $17.1B33.06.0+20%18.2%
Incyte GenomicsINCY $23.4B57.93.9+25%6.7%
IQVIAIQV $40.5B29.12.3+8.8%8.1%
AbsciABSI $1.3Bloss872-47%–
Neurocrine BiosciencesNBIX $15.2B21.74.1+38%19.0%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$19.5M

bought $3K, sold $19.5M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+14%

635 13F filers vs 558

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

over 100%

52.6M shares held by 13F filers (30 Sep 2026) of 47.9M outstanding (24 Oct 2026); above 100%: the share count is probably stale

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

6.2%

3.0M shares sold short (30 Oct 2026) of 47.9M outstanding (24 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

2.2

3.0M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+5.4%

2.8M shares sold short in the report before, 3.0M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

49%

49% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 60%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

388

Tracked since 21 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 21 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

-16%

32 vs 38 applications

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

-2.2%

$982.7M vs $1.0B (quarter ended 26 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

+32%

$46.8M vs $35.6M (quarter ended 26 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

$74.7M

the 12 months before: $59.9M

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$310K

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

73

the 12 months before: 0

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

30

30 articles in the last 7 days; its usual week has 4 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

7.5×

30 articles in the last 7 days; its usual week has 4.

Unusual now sharp changes in the last 90 days, compared with its own past

  • New institutional positions 132, 1.5× a year earlier
  • Layoff notice 2 workers

Price $314.32 on 20 Nov 2026, +94% over 12 months (12-month range $149.93 to $376.10)

  • Sharp change
  • 8-K and other filings
  • WARN layoff notice
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $52.1M in the last 12 months (the 12 months before: $239K).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 31 published in the last 12 months, -21% on the 12 months before.
Revenue per quarter. Revenue $982.7M in the latest quarter, -2.2% on a year earlier.
Capital spending per quarter. Capital spending $46.8M in the latest quarter, +32% on a year earlier.
Institutional holders (13F filers). 635 13F filers reported holding it in the latest 13F quarter, +22% on a year earlier.
Federal obligations. Federal obligations: $63.2M published in the last 12 months, -8.7% on the 12 months before.
Lobbying spend. Lobbying spend: $310K published in the last 12 months, -14% on the 12 months before.
Workers in WARN layoff notices. Workers in WARN layoff notices: 73 published in the last 12 months (none in the 12 months before).

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
17 Nov 2026Sharp changeMany funds opening a new position: many funds opening a new position, 132 vs usual 67 (2026-09-30); 1.5x the same period a year earlier
11 Nov 2026WARN layoff noticeCharles River Laboratories, Inc., 2 workers, Worcester, MA, MA
11 Nov 2026Sharp changeWARN layoff notice: wARN layoff notice (1 event(s) in 30 days, workers total 2)
21 Jul 2026Sharp changeLobbying on a new issue: lobbying on a new issue: FOO (2026-06-30)
9 Jun 2026Sharp changeFederal obligations jump: federal obligations jump, 8.1M vs usual 829K in the same month of earlier years (2026-05-01..2026-05-31); 9.7x the same month a year earlier
11 May 20268-K and other filingsDirector or officer change
28 Apr 2026Sharp changeShort interest spike: short interest spike, 4.7M vs usual 2.6M (2026-04-15); 1.5x the same period a year earlier
14 Apr 2026Sharp changeShort interest spike: short interest spike, 4.6M vs usual 2.6M (2026-03-31); 1.7x the same period a year earlier
10 Apr 2026Lobbying filinglobbying engagement terminated (BGR GOVERNMENT AFFAIRS)
31 Mar 2026Sharp changeShort interest spike: short interest spike, 3.8M vs usual 2.6M (2026-03-13); 1.1x the same period a year earlier
26 Mar 2026WARN layoff noticeCharles River Laboratories, Inc., 71 workers, Wilmington, MA, MA
26 Mar 2026Sharp changeWARN layoff notice: wARN layoff notice (1 event(s) in 30 days, workers total 71)
18 Feb 20268-K and other filingsDirector or officer change
6 Feb 2026Lobbying filingnew lobbying registration (CAPITOL HILL CONSULTING GROUP)
9 Jan 20268-K and other filingsDirector or officer change
9 Jan 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
16 Sep 20258-K and other filingsDirector or officer change
16 Sep 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
23 May 20258-K and other filingsDirector or officer change
7 May 20258-K and other filingsDirector or officer change
7 May 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
29 Apr 2025Sharp changeShort interest spike: short interest spike, 3.0M vs usual 2.0M (2025-04-15); 1.6x the same period a year earlier
1 Apr 2025Sharp changeShort interest spike: short interest spike, 3.3M vs usual 1.9M (2025-03-14); 2.1x the same period a year earlier
18 Mar 2025Sharp changeShort interest spike: short interest spike, 2.9M vs usual 1.9M (2025-02-28); 1.7x the same period a year earlier
7 Jan 2025Sharp changeFederal obligations jump: federal obligations jump, 7.0M vs usual 606K in the same month of earlier years (2024-12-01..2024-12-31); 29.9x the same month a year earlier
7 Nov 2024WARN layoff noticeCharles River Laboratories, Inc., 94 workers, Skokie, IL
7 Nov 2024Sharp changeWARN layoff notice: wARN layoff notice (1 event(s) in 30 days, workers total 94)
21 May 2024Sharp changeMany funds opening a new position: many funds opening a new position, 74 vs usual 54.50 (2024-03-31); 1.3x the same period a year earlier
24 Jan 20248-K and other filingsDirector or officer change
16 Jan 20248-K and other filingsDirector or officer change
16 Jan 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
25 Jul 2023Sharp changeLobbying spend jump: lobbying spend jump, 150K vs usual 60K (2023-06-30); 2.5x the same period a year earlier
7 Jul 2023Lobbying filinglobbying engagement terminated (MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP))
16 May 2023Sharp changeShort interest spike: short interest spike, 1.5M vs usual 1.1M (2023-04-28); 1.4x the same period a year earlier
24 Jan 2023Sharp changeLobbying spend jump: lobbying spend jump, 120K vs usual 50K (2022-12-31); 2.0x the same period a year earlier
20 Jan 2023Sharp changeLobbying on a new issue: lobbying on a new issue: PHA (2022-12-31)
19 Jan 2023Lobbying filingnew lobbying registration (BGR GOVERNMENT AFFAIRS)
6 Dec 2022Sharp changeFederal obligations jump: federal obligations jump, 6.8M vs usual 1.3M in the same month of earlier years (2022-11-01..2022-11-30); 5.5x the same month a year earlier
6 Dec 20228-K and other filingsDirector or officer change
6 Dec 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
13 Oct 2022Lobbying filinglobbying engagement terminated (COVINGTON & BURLING LLP)
31 May 2022Sharp changeShort interest spike: short interest spike, 1.1M vs usual 654K (2022-05-13); 1.7x the same period a year earlier
17 May 2022Sharp changeShort interest spike: short interest spike, 1.1M vs usual 648K (2022-04-29); 1.8x the same period a year earlier
3 May 2022Sharp changeShort interest spike: short interest spike, 1.0M vs usual 648K (2022-04-14); 1.7x the same period a year earlier
12 Apr 2022Sharp changeShort interest spike: short interest spike, 966K vs usual 648K (2022-03-31); 1.5x the same period a year earlier
29 Mar 2022Sharp changeShort interest spike: short interest spike, 1.1M vs usual 648K (2022-03-15); 1.6x the same period a year earlier
28 Mar 20228-K and other filingsDirector or officer change
15 Mar 2022Sharp changeShort interest spike: short interest spike, 1.2M vs usual 648K (2022-02-28); 1.7x the same period a year earlier
1 Mar 2022Sharp changeShort interest spike: short interest spike, 1.1M vs usual 644K (2022-02-15); 1.6x the same period a year earlier
11 Jan 20228-K and other filingsDirector or officer change
27 Dec 20218-K and other filingsDirector or officer change
Insider net buying (open market)
Month from 1 Feb 2022: -$19.9M published
Month from 1 Mar 2022: -$2.5M published
Month from 1 May 2022: -$41K published
Month from 1 Aug 2022: -$45K published
Month from 1 Nov 2022: -$898K published
Month from 1 Dec 2022: -$1.8M published
Month from 1 Feb 2023: -$6.6M published
Month from 1 May 2023: -$307K published
Month from 1 Aug 2023: -$1.5M published
Month from 1 Nov 2023: -$335K published
Month from 1 Dec 2023: -$1.6M published
Month from 1 Feb 2024: -$2.6M published
Month from 1 Mar 2024: -$3.2M published
Month from 1 May 2024: -$374K published
Month from 1 Aug 2024: -$6.6M published
Month from 1 Nov 2024: -$1.6M published
Month from 1 Feb 2025: $537K published
Month from 1 May 2025: -$112K published
Month from 1 Aug 2025: -$186K published
Month from 1 Jan 2026: -$65K published
Month from 1 Mar 2026: $4K published
Month from 1 Jul 2026: -$16.9M published
Month from 1 Aug 2026: -$25.7M published
Month from 1 Oct 2026: -$9.5M published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 9 published
Quarter from 1 Apr 2022: 8 published
Quarter from 1 Jul 2022: 17 published
Quarter from 1 Oct 2022: 7 published
Quarter from 1 Jan 2023: 5 published
Quarter from 1 Apr 2023: 15 published
Quarter from 1 Jul 2023: 13 published
Quarter from 1 Oct 2023: 13 published
Quarter from 1 Jan 2024: 4 published
Quarter from 1 Apr 2024: 10 published
Quarter from 1 Jul 2024: 16 published
Quarter from 1 Oct 2024: 6 published
Quarter from 1 Jan 2025: 8 published
Quarter from 1 Apr 2025: 5 published
Quarter from 1 Jul 2025: 14 published
Quarter from 1 Oct 2025: 12 published
Quarter from 1 Jan 2026: 5 published
Quarter from 1 Apr 2026: 6 published
Quarter from 1 Jul 2026: 17 published
Quarter from 1 Oct 2026: 3 published
Revenue per quarter
Quarter ended 25 Dec 2021: $905.0M, +14% on a year earlier; public on 17 Feb 2022
Quarter ended 26 Mar 2022: $913.9M, +11% on a year earlier; public on 5 May 2022
Quarter ended 25 Jun 2022: $973.1M, +6.4% on a year earlier; public on 4 Aug 2022
Quarter ended 24 Sep 2022: $989.2M, +10% on a year earlier; public on 3 Nov 2022
Quarter ended 31 Dec 2022: $1.1B, +22% on a year earlier; public on 23 Feb 2023
Quarter ended 1 Apr 2023: $1.0B, +13% on a year earlier; public on 12 May 2023
Quarter ended 1 Jul 2023: $1.1B, +8.9% on a year earlier; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $1.0B, +3.8% on a year earlier; public on 9 Nov 2023
Quarter ended 30 Dec 2023: $1.0B, -7.9% on a year earlier; public on 15 Feb 2024
Quarter ended 30 Mar 2024: $1.0B, -1.7% on a year earlier; public on 10 May 2024
Quarter ended 29 Jun 2024: $1.0B, -3.2% on a year earlier; public on 8 Aug 2024
Quarter ended 28 Sep 2024: $1.0B, -1.6% on a year earlier; public on 7 Nov 2024
Quarter ended 28 Dec 2024: $1.0B, -1.1% on a year earlier; public on 20 Feb 2025
Quarter ended 29 Mar 2025: $984.2M, -2.7% on a year earlier; public on 8 May 2025
Quarter ended 28 Jun 2025: $1.0B, +0.6% on a year earlier; public on 7 Aug 2025
Quarter ended 27 Sep 2025: $1.0B, -0.5% on a year earlier; public on 6 Nov 2025
Quarter ended 27 Dec 2025: $994.2M, -0.8% on a year earlier; public on 19 Feb 2026
Quarter ended 28 Mar 2026: $995.8M, +1.2% on a year earlier; public on 8 May 2026
Quarter ended 27 Jun 2026: $1.0B, -2.7% on a year earlier; public on 6 Aug 2026
Quarter ended 26 Sep 2026: $982.7M, -2.2% on a year earlier; public on 5 Nov 2026
Capital spending per quarter
Quarter ended 25 Dec 2021: $98.8M, +12% on a year earlier; public on 17 Feb 2022
Quarter ended 26 Mar 2022: $80.5M, +187% on a year earlier; public on 5 May 2022
Quarter ended 25 Jun 2022: $82.9M, +78% on a year earlier; public on 4 Aug 2022
Quarter ended 24 Sep 2022: $72.4M, +30% on a year earlier; public on 3 Nov 2022
Quarter ended 31 Dec 2022: $89.0M, -9.9% on a year earlier; public on 23 Feb 2023
Quarter ended 1 Apr 2023: $106.9M, +33% on a year earlier; public on 12 May 2023
Quarter ended 1 Jul 2023: $67.4M, -19% on a year earlier; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $65.9M, -8.9% on a year earlier; public on 9 Nov 2023
Quarter ended 30 Dec 2023: $78.3M, -12% on a year earlier; public on 15 Feb 2024
Quarter ended 30 Mar 2024: $79.1M, -26% on a year earlier; public on 10 May 2024
Quarter ended 29 Jun 2024: $39.5M, -41% on a year earlier; public on 8 Aug 2024
Quarter ended 28 Sep 2024: $38.7M, -41% on a year earlier; public on 7 Nov 2024
Quarter ended 28 Dec 2024: $75.6M, -3.5% on a year earlier; public on 20 Feb 2025
Quarter ended 29 Mar 2025: $59.3M, -25% on a year earlier; public on 8 May 2025
Quarter ended 28 Jun 2025: $35.3M, -11% on a year earlier; public on 7 Aug 2025
Quarter ended 27 Sep 2025: $35.6M, -8.1% on a year earlier; public on 6 Nov 2025
Quarter ended 27 Dec 2025: $89.0M, +18% on a year earlier; public on 19 Feb 2026
Quarter ended 28 Mar 2026: $55.9M, -5.8% on a year earlier; public on 8 May 2026
Quarter ended 27 Jun 2026: $31.1M, -12% on a year earlier; public on 6 Aug 2026
Quarter ended 26 Sep 2026: $46.8M, +32% on a year earlier; public on 5 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 626; public on 14 Feb 2022
31 Mar 2022 report: 605; public on 16 May 2022
30 Jun 2022 report: 597; public on 15 Aug 2022
30 Sep 2022 report: 531; public on 14 Nov 2022
31 Dec 2022 report: 571; public on 14 Feb 2023
31 Mar 2023 report: 578; public on 15 May 2023
30 Jun 2023 report: 561; public on 14 Aug 2023
30 Sep 2023 report: 570; public on 14 Nov 2023
31 Dec 2023 report: 596; public on 14 Feb 2024
31 Mar 2024 report: 642; public on 15 May 2024
30 Jun 2024 report: 635; public on 14 Aug 2024
30 Sep 2024 report: 586; public on 14 Nov 2024
31 Dec 2024 report: 607; public on 14 Feb 2025
31 Mar 2025 report: 543; public on 15 May 2025
30 Jun 2025 report: 490; public on 14 Aug 2025
30 Sep 2025 report: 519; public on 14 Nov 2025
31 Dec 2025 report: 556; public on 17 Feb 2026
31 Mar 2026 report: 546; public on 15 May 2026
30 Jun 2026 report: 558; public on 14 Aug 2026
30 Sep 2026 report: 635; public on 16 Nov 2026
Federal obligations
Month from 1 Nov 2021: $1.0M published
Month from 1 Dec 2021: $159K published
Month from 1 Jan 2022: $9.9M published
Month from 1 Feb 2022: -$302K published
Month from 1 Mar 2022: $12.8M published
Month from 1 Apr 2022: -$494K published
Month from 1 May 2022: $3.5M published
Month from 1 Jun 2022: $350K published
Month from 1 Jul 2022: $782K published
Month from 1 Aug 2022: $6.7M published
Month from 1 Sep 2022: $25.9M published
Month from 1 Oct 2022: $760K published
Month from 1 Nov 2022: $1.2M published
Month from 1 Dec 2022: $6.1M published
Month from 1 Jan 2023: $4.1M published
Month from 1 Feb 2023: $4.2M published
Month from 1 Mar 2023: $6.8M published
Month from 1 Apr 2023: $46K published
Month from 1 May 2023: -$276K published
Month from 1 Jun 2023: $1.3M published
Month from 1 Jul 2023: $55K published
Month from 1 Aug 2023: $3.1M published
Month from 1 Sep 2023: $15.5M published
Month from 1 Oct 2023: $2.7M published
Month from 1 Nov 2023: $4.2M published
Month from 1 Dec 2023: $212K published
Month from 1 Jan 2024: $3.2M published
Month from 1 Feb 2024: $6.5M published
Month from 1 Mar 2024: $918K published
Month from 1 Apr 2024: -$19K published
Month from 1 May 2024: $25K published
Month from 1 Aug 2024: $2.0M published
Month from 1 Sep 2024: $6.1M published
Month from 1 Oct 2024: $1.5M published
Month from 1 Nov 2024: $13K published
Month from 1 Dec 2024: $7.0M published
Month from 1 Jan 2025: $110K published
Month from 1 Feb 2025: $2.5M published
Month from 1 Mar 2025: $4.9M published
Month from 1 Apr 2025: $296K published
Month from 1 May 2025: $794K published
Month from 1 Jun 2025: $34.9M published
Month from 1 Jul 2025: -$148K published
Month from 1 Aug 2025: $187K published
Month from 1 Sep 2025: $14.1M published
Month from 1 Oct 2025: $4.7M published
Month from 1 Nov 2025: $6K published
Month from 1 Dec 2025: $2.6M published
Month from 1 Jan 2026: $2.2M published
Month from 1 Feb 2026: $483K published
Month from 1 Mar 2026: $40.5M published
Month from 1 Apr 2026: $14K published
Month from 1 May 2026: $9.1M published
Month from 1 Jun 2026: $759K published
Month from 1 Jul 2026: $46K published
Month from 1 Aug 2026: $739K published
Month from 1 Sep 2026: $6.8M published
Month from 1 Oct 2026: $374K published
Month from 1 Nov 2026: -$417K published
Lobbying spend
Quarter from 1 Jan 2022: $60K published
Quarter from 1 Apr 2022: $60K published
Quarter from 1 Jul 2022: $60K published
Quarter from 1 Oct 2022: $60K published
Quarter from 1 Jan 2023: $120K published
Quarter from 1 Apr 2023: $240K published
Quarter from 1 Jul 2023: $150K published
Quarter from 1 Oct 2023: $90K published
Quarter from 1 Jan 2024: $90K published
Quarter from 1 Apr 2024: $90K published
Quarter from 1 Jul 2024: $90K published
Quarter from 1 Oct 2024: $90K published
Quarter from 1 Jan 2025: $90K published
Quarter from 1 Apr 2025: $90K published
Quarter from 1 Jul 2025: $90K published
Quarter from 1 Oct 2025: $90K published
Quarter from 1 Jan 2026: $90K published
Quarter from 1 Apr 2026: $70K published
Quarter from 1 Jul 2026: $70K published
Quarter from 1 Oct 2026: $80K published
Workers in WARN layoff notices
Month from 1 Nov 2024: 94 published
Month from 1 Mar 2026: 71 published
Month from 1 Nov 2026: 2 published

What is unusual now

  • Made public in the last 90 days: it saw 132 13F filers open a new position in the quarter ended 30 Sep 2026, 1.5× the same quarter last year; it also filed a WARN layoff notice covering 2 workers within 30 days (Worcester, MA, MA). Two or more unrelated kinds of activity agreed on 17 Nov 2026.
  • Federal obligations jump: booked $8.1M in federal contract and grant obligations in May 2026, 9.7× the same month last year Public on 3 Jun 2026.
  • Many funds opening a new position: saw 132 13F filers open a new position in the quarter ended 30 Sep 2026, 1.5× the same quarter last year Public on 16 Nov 2026.
  • WARN layoff notice: filed a WARN layoff notice covering 2 workers within 30 days (Worcester, MA, MA) Public on 11 Nov 2026.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 4 sales, $19.5M; 1 purchase, $3K. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
26 Oct 2026James C FosterDirectorSellplanned in advance (10b5-1); after exercising options24,042$350.00$8.4MForm 4
23 Oct 2026Shannon M ParisottoCEVP, Disc & Safety AssessmentSellplanned in advance (10b5-1); after exercising options2,156$344.41$743KForm 4
7 Oct 2026Shannon M ParisottoCEVP, Disc & Safety AssessmentSellplanned in advance (10b5-1); after exercising options981$308.44$303KForm 4
2 Oct 2026Glenn ColemanEVP & Chief Financial OfficerBuy10$297.43$3KForm 4
27 Aug 2026James C FosterDirectorSellplanned in advance (10b5-1); after exercising options33,561$300.00$10.1MForm 4
20 Aug 2026Shannon M ParisottoCEVP, Disc & Safety AssessmentSellplanned in advance (10b5-1); after exercising options2,039$294.12$600KForm 4
20 Aug 2026Nancy C AndrewsDirectorSellafter exercising options573$285.24$163KForm 4
13 Aug 2026Birgit GirshickChief Executive OfficerSellplanned in advance (10b5-1); after exercising options6,500$279.90$1.8MForm 4

635 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 129 opened a position, 55 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
FMR LLC (Fidelity)6.0M12.5%$1.8B+1.7M+41%
BlackRock, Inc.3.8M7.88%$1.1B-21K-0.6%
Vanguard Capital Management LLC3.1M6.53%$922.7M-21K-0.7%
T. Rowe Price Associates Inc3.0M6.28%+1.5M+100%
Vanguard Portfolio Management LLC2.2M4.57%$645.8M-22K-1.0%
State Street Corp1.9M3.91%$552.8M+9,587+0.5%
Invesco Ltd.1.9M3.87%$546.5M-1.1M-38%
Harris Associates L P1.4M2.94%$416.1M-831K-37%
Geode Capital Management, LLC1.3M2.71%$382.9M-5,563-0.4%
Ariel Investments, LLC1.2M2.49%$352.0M-313K-21%

Federal contracts

All 87 federal contracts

5 new awards in 12 months, $19.2M obligated when signed. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
17 Sep 2026Department of Health and Human ServicesNational Institutes of Health$2.7MTASK ORDER 04 FOR CONTRACT 75N95023D00024 IS AWARDED IN ACCORDANCE WITH THE STATEMENT OF WORK FOR DEVELOPMENT AND MAINTENANCE OF A MULTIGENOTYPIC AGED RAT COLONYUSAspending
17 Sep 2026Department of Health and Human ServicesNational Institutes of Health$8.2MTASK ORDER 5 FOR THE DEVELOPMENT AND MAINTENANCE OF A MULTIGENOTYPIC AGED MOUSE COLONY.USAspending
31 Aug 2026Department of Health and Human ServicesNational Institutes of Health$1.0MCLINICAL TRIAL MATERIALS FOR VIRUS VACCINES. HISTORIC H3N2 AND H10N7 INFLUENZA CHALLENGE VIRUSES. TASK ORDER 15.USAspending
28 Feb 2026Department of Health and Human ServicesNational Institutes of Health$5.3Mup to $43.3MNATIONAL INSTITUTES OF HEALTH (NIH), NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE (NINDS), ANIMAL CARE AND RESEARCH SUPPORT SERVICES LARC-2025-NINDS-0010USAspending
20 Jan 2026Department of Health and Human ServicesNational Institutes of Health$1.9MDEVELOPMENT AND MAINTENANCE OF A MULTIGENOTYPIC AGED RAT COLONYUSAspending
29 Sep 2025Department of Health and Human ServicesNational Institutes of Health$4.7MPREPARATION AND CHARACTERIZATION OF FIVE VACCINE CANDIDATESUSAspending
22 Sep 2025Department of Health and Human ServicesNational Institutes of Health$1.1MTASK ORDER FOR CONTRACT 75N95023D00024 IS AWARDED IN ACCORDANCE WITH THE ATTACHED STATEMENT OF WORK AND CHARLES RIVER'S FINAL PROPOSAL REVISIONS (FPR) DATED 9/2/2025.USAspending
22 Sep 2025Department of Health and Human ServicesNational Institutes of Health$7.2MTASK ORDER 4 FOR THE DEVELOPMENT AND MAINTENANCE OF A MULTIGENOTYPIC AGED MOUSE COLONY.USAspending

Company events

All 41 company events

In 12 months: 3 director or officer changes. Results releases and routine reports are left out.

FiledWhat happenedSource
11 May 2026Director or officer changeSame filing: shareholder vote results8-K
18 Feb 2026Director or officer change8-K
9 Jan 2026Director or officer change8-K
16 Sep 2025Director or officer change8-K
23 May 2025Director or officer changeSame filing: shareholder vote results8-K
7 May 2025Director or officer change; Signed a major agreement8-K
24 Jan 2024Director or officer change8-K
16 Jan 2024Director or officer change8-K

388 open postings; careers site tracked since 21 Nov 2026. Most in Research & science 12%, Operations & administration 10%, Legal, policy & compliance 6%, People & recruiting 3%.

PostedJobLocation
21 Nov 2026or earlierResearch Analyst IResearch & scienceReno, NV, US, 89511
21 Nov 2026or earlierAnimal Support Technician ICambridge, MA, US, 02142
21 Nov 2026or earlierAnimal Care Technician IBoston, MA, US, 02210
21 Nov 2026or earlierTechnician I, Sample Processing - 2nd ShiftAshland, OH, US, 44805
21 Nov 2026or earlierAnimal CaretakerBaltimore, MD, US, 21224
21 Nov 2026or earlierAnimal Support Technician IICambridge, MA, US, 02142
21 Nov 2026or earlierAnimal CaretakerBaltimore, MD, US, 21224
21 Nov 2026or earlierAnimal Caretaker IBethesda, MD, US, 20892

Reported lobbying spend: $80K in Q3 2026, $70K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
9 Jan 2026NewCapitol Hill Consulting Groupfor Charles River Laboratories International, IncIssues surrounding improvements to clinical research capabilities and modernization of research methods.Health issues, FOO, PharmacyFiling
1 Jan 2026EndedBGR Government Affairsfor Charles River LaboratoriesNot statedFiling
31 May 2023EndedMcguirewoods Consulting (A Subsidiary Of Mcguirewoods LLP)for Charles River LaboratoriesWork on the need for Limulus Amebocyte Lysate (LAL) product and synthetic products to be regulated similarly in terms of safety and effectivenessHealth issuesFiling
1 Dec 2022NewBGR Government Affairsfor Charles River LaboratoriesProvide strategic counsel and advocacy for issues related to the non-human primate supply chain for research and practical applications of invitro alternatives in research.Pharmacy, ANIFiling
1 Jul 2022EndedCovington & Burling LLPfor Charles River LaboratoriesNot statedFiling
26 Jul 2021NewMcguirewoods Consulting (A Subsidiary Of Mcguirewoods LLP)for Charles River LaboratoriesWork on the need for Limulus Amebocyte Lysate (LAL) product and synthetic products to be regulated similarity in terms of safety and effectivenessHealth issuesFiling
31 Mar 2021EndedK&L Gates, LLPfor Charles River Laboratories International, Inc.Not statedFiling
6 Aug 2020NewCovington & Burling LLPfor Charles River LaboratoriesStandards for developing synthetic alternatives for bacterial endotoxin testingHealth issuesFiling

Layoff notices

All 3 layoff notices

1 notice in 12 months covering 2 workers. State WARN notices.

NoticeSiteWorkersJobs endSource
10 Nov 2026Charles River Laboratories, Inc.Worcester, MA, MA231 Jan 2027Notice
10 Nov 2025Charles River Laboratories, Inc.Wilmington, MA, MA7124 Apr 2026Notice
6 Nov 2024Charles River Laboratories, Inc.Cook County, IL9431 Jan 2025closureNotice

The 5 newest of 218 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

17 Nov 2026confirmed

Confirmed across sources Institutional holdings and Layoff notices

Charles River Laboratories International (CRL): filed a WARN layoff notice covering 2 workers within 30 days (Worcester, MA, MA), while it saw 132 13F filers open a new position in the quarter ended 30 Sep 2026, 1.5× the same quarter last year. Two unrelated kinds of activity within 6 days.

  • Layoff notices: WARN layoff notice, became public on 11 Nov 2026
  • Institutional holdings: Many funds opening a new position, became public on 16 Nov 2026
2024-09-30: 542024-12-31: 652025-03-31: 562025-06-30: 772025-09-30: 892025-12-31: 922026-03-31: 582026-06-30: 692026-09-30: 132
The quarter ended 30 Sep 2026 against the 8 quarters before it. this quarterearliernormal: 67
See the evidence (2 changes)

Layoff notices: WARN layoff notice became public on 11 Nov 2026

Charles River Laboratories International filed a WARN layoff notice covering 2 workers within 30 days (Worcester, MA, MA).

Notices in the window
1
Workers named
2
Window
12 Oct 2026 to 11 Nov 2026

Fires on a WARN notice after 30 days without one; notices within 30 days are summed.

Institutional holdings: Many funds opening a new position became public on 16 Nov 2026

Charles River Laboratories International saw 132 13F filers open a new position in the quarter ended 30 Sep 2026, 1.5× the same quarter last year.

This period
132 (the quarter ended 30 Sep 2026)
Normal quarter (median of 8 earlier)
67
Typical spread (median absolute deviation)
10.5
How far from its usual level
+4.2
Same quarter last year
89
History used
4,748 days
2024-09-30: 542024-12-31: 652025-03-31: 562025-06-30: 772025-09-30: 892025-12-31: 922026-03-31: 582026-06-30: 692026-09-30: 132
the quarter ended 30 Sep 20268 earlier quartersnormal: 67

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

31 Mar 2026confirmed

Confirmed across sources Layoff notices and Short interest and volume

Charles River Laboratories International (CRL): filed a WARN layoff notice covering 71 workers within 30 days (Wilmington, MA, MA), while it had 4.7M shares sold short in the 15 Apr 2026 report, 1.5× the same report last year. Two unrelated kinds of activity within 33 days.

  • Layoff notices: WARN layoff notice, became public on 26 Mar 2026
  • Short interest and volume: Short interest spike, became public on 25 Mar 2026
  • Short interest and volume: Short interest spike, became public on 11 Apr 2026
  • Short interest and volume: Short interest spike, became public on 25 Apr 2026
2025-04-15: 3.0M2025-04-30: 2.6M2025-05-15: 2.8M2025-05-30: 2.4M2025-06-13: 2.6M2025-06-30: 2.4M2025-07-15: 2.3M2025-07-31: 2.2M2025-08-15: 3.0M2025-08-29: 2.7M2025-09-15: 2.6M2025-09-30: 2.2M2025-10-15: 2.1M2025-10-31: 2.4M2025-11-14: 2.7M2025-11-28: 2.6M2025-12-15: 2.4M2025-12-31: 2.6M2026-01-15: 2.8M2026-01-30: 2.7M2026-02-13: 3.0M2026-02-27: 3.5M2026-03-13: 3.8M2026-03-31: 4.6M2026-04-15: 4.7M
The 15 Apr 2026 report against the 24 reports before it. this reportearliernormal: 2.6M
See the evidence (4 changes)

Layoff notices: WARN layoff notice became public on 26 Mar 2026

Charles River Laboratories International filed a WARN layoff notice covering 71 workers within 30 days (Wilmington, MA, MA).

Notices in the window
1
Workers named
71
Window
24 Feb 2026 to 26 Mar 2026

Fires on a WARN notice after 30 days without one; notices within 30 days are summed.

Short interest and volume: Short interest spike became public on 25 Mar 2026

Charles River Laboratories International had 3.8M shares sold short in the 13 Mar 2026 report, 1.1× the same report last year.

This period
3.8M (the 13 Mar 2026 report)
Normal report (median of 24 earlier)
2.6M
Typical spread (median absolute deviation)
207K
How far from its usual level
+3.7
Same report last year
3.3M
History used
2,996 days
2025-03-14: 3.3M2025-03-31: 2.7M2025-04-15: 3.0M2025-04-30: 2.6M2025-05-15: 2.8M2025-05-30: 2.4M2025-06-13: 2.6M2025-06-30: 2.4M2025-07-15: 2.3M2025-07-31: 2.2M2025-08-15: 3.0M2025-08-29: 2.7M2025-09-15: 2.6M2025-09-30: 2.2M2025-10-15: 2.1M2025-10-31: 2.4M2025-11-14: 2.7M2025-11-28: 2.6M2025-12-15: 2.4M2025-12-31: 2.6M2026-01-15: 2.8M2026-01-30: 2.7M2026-02-13: 3.0M2026-02-27: 3.5M2026-03-13: 3.8M
the 13 Mar 2026 report24 earlier reportsnormal: 2.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 Apr 2026

Charles River Laboratories International had 4.6M shares sold short in the 31 Mar 2026 report, 1.7× the same report last year.

This period
4.6M (the 31 Mar 2026 report)
Normal report (median of 24 earlier)
2.6M
Typical spread (median absolute deviation)
207K
How far from its usual level
+6.4
Same report last year
2.7M
History used
3,014 days
2025-03-31: 2.7M2025-04-15: 3.0M2025-04-30: 2.6M2025-05-15: 2.8M2025-05-30: 2.4M2025-06-13: 2.6M2025-06-30: 2.4M2025-07-15: 2.3M2025-07-31: 2.2M2025-08-15: 3.0M2025-08-29: 2.7M2025-09-15: 2.6M2025-09-30: 2.2M2025-10-15: 2.1M2025-10-31: 2.4M2025-11-14: 2.7M2025-11-28: 2.6M2025-12-15: 2.4M2025-12-31: 2.6M2026-01-15: 2.8M2026-01-30: 2.7M2026-02-13: 3.0M2026-02-27: 3.5M2026-03-13: 3.8M2026-03-31: 4.6M
the 31 Mar 2026 report24 earlier reportsnormal: 2.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Apr 2026

Charles River Laboratories International had 4.7M shares sold short in the 15 Apr 2026 report, 1.5× the same report last year.

This period
4.7M (the 15 Apr 2026 report)
Normal report (median of 24 earlier)
2.6M
Typical spread (median absolute deviation)
213K
How far from its usual level
+6.5
Same report last year
3.0M
History used
3,029 days
2025-04-15: 3.0M2025-04-30: 2.6M2025-05-15: 2.8M2025-05-30: 2.4M2025-06-13: 2.6M2025-06-30: 2.4M2025-07-15: 2.3M2025-07-31: 2.2M2025-08-15: 3.0M2025-08-29: 2.7M2025-09-15: 2.6M2025-09-30: 2.2M2025-10-15: 2.1M2025-10-31: 2.4M2025-11-14: 2.7M2025-11-28: 2.6M2025-12-15: 2.4M2025-12-31: 2.6M2026-01-15: 2.8M2026-01-30: 2.7M2026-02-13: 3.0M2026-02-27: 3.5M2026-03-13: 3.8M2026-03-31: 4.6M2026-04-15: 4.7M
the 15 Apr 2026 report24 earlier reportsnormal: 2.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

17 Aug 2021confirmed

Confirmed across sources Institutional holdings and Filings + Financials

Charles River Laboratories International (CRL): spent $46.4M on capital projects in the quarter ended 26 Jun 2021, 1.7× the same quarter last year, while it saw 106 13F filers open a new position in the quarter ended 30 Jun 2021, 1.3× the same quarter last year. Two unrelated kinds of activity within 7 days.

  • Financials: Quarterly capital spending jump, became public on 10 Aug 2021
  • Financials: Quarterly revenue change, became public on 10 Aug 2021
  • Institutional holdings: Many funds opening a new position, became public on 16 Aug 2021
2019-06-29: $24.8M2019-09-28: $35.2M2019-12-28: $63.8M2020-03-28: $25.7M2020-06-27: $26.8M2020-09-26: $26.2M2020-12-26: $87.9M2021-03-27: $28.0M2021-06-26: $46.4M
The quarter ended 26 Jun 2021 against the 8 quarters before it. this quarterearliernormal: $27.4M
See the evidence (3 changes)

Financials: Quarterly capital spending jump became public on 10 Aug 2021

Charles River Laboratories International spent $46.4M on capital projects in the quarter ended 26 Jun 2021, 1.7× the same quarter last year.

This period
$46.4M (the quarter ended 26 Jun 2021)
Normal quarter (median of 8 earlier)
$27.4M
Typical spread (median absolute deviation)
$2.2M
How far from its usual level
+5.9
Same quarter last year
$26.8M
History used
4,291 days
2019-06-29: $24.8M2019-09-28: $35.2M2019-12-28: $63.8M2020-03-28: $25.7M2020-06-27: $26.8M2020-09-26: $26.2M2020-12-26: $87.9M2021-03-27: $28.0M2021-06-26: $46.4M
the quarter ended 26 Jun 20218 earlier quartersnormal: $27.4M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

Check it at the source: SEC EDGAR quarterly reports.

Financials: Quarterly revenue change became public on 10 Aug 2021

Charles River Laboratories International reported revenue of $914.6M for the quarter ended 26 Jun 2021, 1.3× the same quarter last year.

This period
$914.6M (the quarter ended 26 Jun 2021)
Normal quarter (median of 8 earlier)
$699.1M
Typical spread (median absolute deviation)
$36.3M
How far from its usual level
+3.1
Same quarter last year
$682.6M
History used
4,382 days
2019-06-29: $657.6M2019-09-28: $668.0M2019-12-28: $691.1M2020-03-28: $707.1M2020-06-27: $682.6M2020-09-26: $743.3M2020-12-26: $791.0M2021-03-27: $824.6M2021-06-26: $914.6M
the quarter ended 26 Jun 20218 earlier quartersnormal: $699.1M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Institutional holdings: Many funds opening a new position became public on 16 Aug 2021

Charles River Laboratories International saw 106 13F filers open a new position in the quarter ended 30 Jun 2021, 1.3× the same quarter last year.

This period
106 (the quarter ended 30 Jun 2021)
Normal quarter (median of 8 earlier)
57.5
Typical spread (median absolute deviation)
9
How far from its usual level
+3.6
Same quarter last year
80
History used
2,830 days
2019-06-30: 372019-09-30: 312019-12-31: 462020-03-31: 552020-06-30: 802020-09-30: 642020-12-31: 602021-03-31: 612021-06-30: 106
the quarter ended 30 Jun 20218 earlier quartersnormal: 57.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 17 Nov 2026several at once

    filed a WARN layoff notice covering 2 workers within 30 days (Worcester, MA, MA), while it saw 132 13F filers open a new position in the quarter ended 30 Sep 2026, 1.5× the same quarter last year. Two unrelated kinds of activity within 6 days.

    See the evidence (2 changes)

    Layoff notices: WARN layoff notice became public on 11 Nov 2026

    Charles River Laboratories International filed a WARN layoff notice covering 2 workers within 30 days (Worcester, MA, MA).

    Notices in the window
    1
    Workers named
    2
    Window
    12 Oct 2026 to 11 Nov 2026

    Fires on a WARN notice after 30 days without one; notices within 30 days are summed.

    Institutional holdings: Many funds opening a new position became public on 16 Nov 2026

    Charles River Laboratories International saw 132 13F filers open a new position in the quarter ended 30 Sep 2026, 1.5× the same quarter last year.

    This period
    132 (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    67
    Typical spread (median absolute deviation)
    10.5
    How far from its usual level
    +4.2
    Same quarter last year
    89
    History used
    4,748 days
    2024-09-30: 542024-12-31: 652025-03-31: 562025-06-30: 772025-09-30: 892025-12-31: 922026-03-31: 582026-06-30: 692026-09-30: 132
    the quarter ended 30 Sep 20268 earlier quartersnormal: 67

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  2. 16 Nov 2026Institutional holdings change

    saw 132 13F filers open a new position in the quarter ended 30 Sep 2026, 1.5× the same quarter last year.

    Same quarter last year: 89; its normal quarter is 67.

    See the evidence
    This period
    132 (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    67
    Typical spread (median absolute deviation)
    10.5
    How far from its usual level
    +4.2
    Same quarter last year
    89
    History used
    4,748 days
    2024-09-30: 542024-12-31: 652025-03-31: 562025-06-30: 772025-09-30: 892025-12-31: 922026-03-31: 582026-06-30: 692026-09-30: 132
    the quarter ended 30 Sep 20268 earlier quartersnormal: 67

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  3. 11 Nov 2026Layoff notices change

    filed a WARN layoff notice covering 2 workers within 30 days (Worcester, MA, MA).

    See the evidence (1 source record)
    Notices in the window
    1
    Workers named
    2
    Window
    12 Oct 2026 to 11 Nov 2026

    Fires on a WARN notice after 30 days without one; notices within 30 days are summed.

  4. 11 Nov 2026Layoff notices record

    WARN notice: Charles River Laboratories, Inc., 2 workers, Worcester, MA, MA (dated 10 Nov 2026)

  5. 2 Oct 2026Insiders record

    Coleman Glenn (EVP & Chief Financial Officer) bought 10 shares of CRL ($2,974)

  6. 23 Sep 2026Government contracts record

    CHARLES RIVER LABORATORIES, INC.: new Department of Health and Human Services contract 75N98026F00001 ($2.7M) (dated 17 Sep 2026)

  7. 23 Sep 2026Government contracts record

    CHARLES RIVER LABORATORIES, INC.: new Department of Health and Human Services contract 75N98026F00001 ($8.2M) (dated 17 Sep 2026)

  8. 6 Sep 2026Government contracts record

    CHARLES RIVER LABORATORIES, INC.: new Department of Health and Human Services contract 75N98026F00004 ($1.0M) (dated 31 Aug 2026)

  9. 21 Jul 2026Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['FOO']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    10529729
  10. 3 Jun 2026Government contracts change

    booked $8.1M in federal contract and grant obligations in May 2026, 9.7× the same month last year.

    Same month last year: $829K; its normal month is $829K.

    See the evidence
    This period
    $8.1M (May 2026)
    Normal month (median of 5 earlier)
    $829K
    Typical spread (median absolute deviation)
    $770K
    How far from its usual level
    +6.3
    Same month last year
    $829K
    History used
    6,817 days
    2021-05-01: $59K2022-05-01: $3.1M2023-05-01: $936K2024-05-01: $02025-05-01: $829K2026-05-01: $8.1M
    May 20265 earlier monthsnormal: $829K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.

    Check it at the source: USAspending.gov award search.

  11. 11 May 2026Filings record

    Director or officer change

  12. 25 Apr 2026Short interest and volume change

    had 4.7M shares sold short in the 15 Apr 2026 report, 1.5× the same report last year.

    Same report last year: 3.0M; its normal report is 2.6M.

    See the evidence
    This period
    4.7M (the 15 Apr 2026 report)
    Normal report (median of 24 earlier)
    2.6M
    Typical spread (median absolute deviation)
    213K
    How far from its usual level
    +6.5
    Same report last year
    3.0M
    History used
    3,029 days
    2025-04-15: 3.0M2025-04-30: 2.6M2025-05-15: 2.8M2025-05-30: 2.4M2025-06-13: 2.6M2025-06-30: 2.4M2025-07-15: 2.3M2025-07-31: 2.2M2025-08-15: 3.0M2025-08-29: 2.7M2025-09-15: 2.6M2025-09-30: 2.2M2025-10-15: 2.1M2025-10-31: 2.4M2025-11-14: 2.7M2025-11-28: 2.6M2025-12-15: 2.4M2025-12-31: 2.6M2026-01-15: 2.8M2026-01-30: 2.7M2026-02-13: 3.0M2026-02-27: 3.5M2026-03-13: 3.8M2026-03-31: 4.6M2026-04-15: 4.7M
    the 15 Apr 2026 report24 earlier reportsnormal: 2.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  13. 11 Apr 2026Short interest and volume change

    had 4.6M shares sold short in the 31 Mar 2026 report, 1.7× the same report last year.

    Same report last year: 2.7M; its normal report is 2.6M.

    See the evidence
    This period
    4.6M (the 31 Mar 2026 report)
    Normal report (median of 24 earlier)
    2.6M
    Typical spread (median absolute deviation)
    207K
    How far from its usual level
    +6.4
    Same report last year
    2.7M
    History used
    3,014 days
    2025-03-31: 2.7M2025-04-15: 3.0M2025-04-30: 2.6M2025-05-15: 2.8M2025-05-30: 2.4M2025-06-13: 2.6M2025-06-30: 2.4M2025-07-15: 2.3M2025-07-31: 2.2M2025-08-15: 3.0M2025-08-29: 2.7M2025-09-15: 2.6M2025-09-30: 2.2M2025-10-15: 2.1M2025-10-31: 2.4M2025-11-14: 2.7M2025-11-28: 2.6M2025-12-15: 2.4M2025-12-31: 2.6M2026-01-15: 2.8M2026-01-30: 2.7M2026-02-13: 3.0M2026-02-27: 3.5M2026-03-13: 3.8M2026-03-31: 4.6M
    the 31 Mar 2026 report24 earlier reportsnormal: 2.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  14. 10 Apr 2026Lobbying record

    CHARLES RIVER LABORATORIES: lobbying engagement terminated (BGR GOVERNMENT AFFAIRS) (dated 1 Jan 2026)

  15. 31 Mar 2026several at once

    filed a WARN layoff notice covering 71 workers within 30 days (Wilmington, MA, MA), while it had 4.7M shares sold short in the 15 Apr 2026 report, 1.5× the same report last year. Two unrelated kinds of activity within 33 days.

    See the evidence (4 changes)

    Layoff notices: WARN layoff notice became public on 26 Mar 2026

    Charles River Laboratories International filed a WARN layoff notice covering 71 workers within 30 days (Wilmington, MA, MA).

    Notices in the window
    1
    Workers named
    71
    Window
    24 Feb 2026 to 26 Mar 2026

    Fires on a WARN notice after 30 days without one; notices within 30 days are summed.

    Short interest and volume: Short interest spike became public on 25 Mar 2026

    Charles River Laboratories International had 3.8M shares sold short in the 13 Mar 2026 report, 1.1× the same report last year.

    This period
    3.8M (the 13 Mar 2026 report)
    Normal report (median of 24 earlier)
    2.6M
    Typical spread (median absolute deviation)
    207K
    How far from its usual level
    +3.7
    Same report last year
    3.3M
    History used
    2,996 days
    2025-03-14: 3.3M2025-03-31: 2.7M2025-04-15: 3.0M2025-04-30: 2.6M2025-05-15: 2.8M2025-05-30: 2.4M2025-06-13: 2.6M2025-06-30: 2.4M2025-07-15: 2.3M2025-07-31: 2.2M2025-08-15: 3.0M2025-08-29: 2.7M2025-09-15: 2.6M2025-09-30: 2.2M2025-10-15: 2.1M2025-10-31: 2.4M2025-11-14: 2.7M2025-11-28: 2.6M2025-12-15: 2.4M2025-12-31: 2.6M2026-01-15: 2.8M2026-01-30: 2.7M2026-02-13: 3.0M2026-02-27: 3.5M2026-03-13: 3.8M
    the 13 Mar 2026 report24 earlier reportsnormal: 2.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 11 Apr 2026

    Charles River Laboratories International had 4.6M shares sold short in the 31 Mar 2026 report, 1.7× the same report last year.

    This period
    4.6M (the 31 Mar 2026 report)
    Normal report (median of 24 earlier)
    2.6M
    Typical spread (median absolute deviation)
    207K
    How far from its usual level
    +6.4
    Same report last year
    2.7M
    History used
    3,014 days
    2025-03-31: 2.7M2025-04-15: 3.0M2025-04-30: 2.6M2025-05-15: 2.8M2025-05-30: 2.4M2025-06-13: 2.6M2025-06-30: 2.4M2025-07-15: 2.3M2025-07-31: 2.2M2025-08-15: 3.0M2025-08-29: 2.7M2025-09-15: 2.6M2025-09-30: 2.2M2025-10-15: 2.1M2025-10-31: 2.4M2025-11-14: 2.7M2025-11-28: 2.6M2025-12-15: 2.4M2025-12-31: 2.6M2026-01-15: 2.8M2026-01-30: 2.7M2026-02-13: 3.0M2026-02-27: 3.5M2026-03-13: 3.8M2026-03-31: 4.6M
    the 31 Mar 2026 report24 earlier reportsnormal: 2.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 25 Apr 2026

    Charles River Laboratories International had 4.7M shares sold short in the 15 Apr 2026 report, 1.5× the same report last year.

    This period
    4.7M (the 15 Apr 2026 report)
    Normal report (median of 24 earlier)
    2.6M
    Typical spread (median absolute deviation)
    213K
    How far from its usual level
    +6.5
    Same report last year
    3.0M
    History used
    3,029 days
    2025-04-15: 3.0M2025-04-30: 2.6M2025-05-15: 2.8M2025-05-30: 2.4M2025-06-13: 2.6M2025-06-30: 2.4M2025-07-15: 2.3M2025-07-31: 2.2M2025-08-15: 3.0M2025-08-29: 2.7M2025-09-15: 2.6M2025-09-30: 2.2M2025-10-15: 2.1M2025-10-31: 2.4M2025-11-14: 2.7M2025-11-28: 2.6M2025-12-15: 2.4M2025-12-31: 2.6M2026-01-15: 2.8M2026-01-30: 2.7M2026-02-13: 3.0M2026-02-27: 3.5M2026-03-13: 3.8M2026-03-31: 4.6M2026-04-15: 4.7M
    the 15 Apr 2026 report24 earlier reportsnormal: 2.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  16. 26 Mar 2026Layoff notices change

    filed a WARN layoff notice covering 71 workers within 30 days (Wilmington, MA, MA).

    See the evidence (1 source record)
    Notices in the window
    1
    Workers named
    71
    Window
    24 Feb 2026 to 26 Mar 2026

    Fires on a WARN notice after 30 days without one; notices within 30 days are summed.

  17. 26 Mar 2026Layoff notices record

    WARN notice: Charles River Laboratories, Inc., 71 workers, Wilmington, MA, MA (dated 10 Nov 2025)

  18. 25 Mar 2026Short interest and volume change

    had 3.8M shares sold short in the 13 Mar 2026 report, 1.1× the same report last year.

    Same report last year: 3.3M; its normal report is 2.6M.

    See the evidence
    This period
    3.8M (the 13 Mar 2026 report)
    Normal report (median of 24 earlier)
    2.6M
    Typical spread (median absolute deviation)
    207K
    How far from its usual level
    +3.7
    Same report last year
    3.3M
    History used
    2,996 days
    2025-03-14: 3.3M2025-03-31: 2.7M2025-04-15: 3.0M2025-04-30: 2.6M2025-05-15: 2.8M2025-05-30: 2.4M2025-06-13: 2.6M2025-06-30: 2.4M2025-07-15: 2.3M2025-07-31: 2.2M2025-08-15: 3.0M2025-08-29: 2.7M2025-09-15: 2.6M2025-09-30: 2.2M2025-10-15: 2.1M2025-10-31: 2.4M2025-11-14: 2.7M2025-11-28: 2.6M2025-12-15: 2.4M2025-12-31: 2.6M2026-01-15: 2.8M2026-01-30: 2.7M2026-02-13: 3.0M2026-02-27: 3.5M2026-03-13: 3.8M
    the 13 Mar 2026 report24 earlier reportsnormal: 2.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  19. 6 Mar 2026Government contracts record

    CHARLES RIVER LABORATORIES, INC.: new Department of Health and Human Services contract 75N98026F00002 ($5.5M) (dated 28 Feb 2026)

  20. 5 Mar 2026Insiders record

    LaPlume Joseph W (EVP, Corp Strategy & Develop) bought 25 shares of CRL ($4,364) (dated 4 Mar 2026)

  21. 18 Feb 2026Filings record

    Director or officer change

  22. 6 Feb 2026Lobbying record

    CHARLES RIVER LABORATORIES INTERNATIONAL, INC: new lobbying registration (CAPITOL HILL CONSULTING GROUP) (dated 9 Jan 2026)

  23. 26 Jan 2026Government contracts record

    CHARLES RIVER LABORATORIES, INC.: new Department of Health and Human Services contract 75N95026F00001 ($1.9M) (dated 20 Jan 2026)

  24. 9 Jan 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  25. 9 Jan 2026Filings record

    Director or officer change

  26. 5 Oct 2025Government contracts record

    CHARLES RIVER LABORATORIES, INC.: new Department of Health and Human Services contract 75N93025F00001 ($4.7M) (dated 29 Sep 2025)

  27. 28 Sep 2025Government contracts record

    CHARLES RIVER LABORATORIES, INC.: new Department of Health and Human Services contract 75N95025F00001 ($1.1M) (dated 22 Sep 2025)

  28. 28 Sep 2025Government contracts record

    CHARLES RIVER LABORATORIES, INC.: new Department of Health and Human Services contract 75N95025F00001 ($7.2M) (dated 22 Sep 2025)

  29. 16 Sep 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  30. 16 Sep 2025Filings record

    Director or officer change

  31. 14 Sep 2025Government contracts record

    CHARLES RIVER LABORATORIES, INC.: new Department of Health and Human Services contract 75N98025F00012 ($3.4M) (dated 8 Sep 2025)

  32. 9 Sep 2025Government contracts record

    CHARLES RIVER LABORATORIES, INC.: new Department of Health and Human Services contract 75N98025F00011 ($4.7M) (dated 3 Sep 2025)

  33. 23 May 2025Filings record

    Director or officer change

  34. 7 May 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  35. 7 May 2025Filings record

    Director or officer change

  36. 26 Apr 2025Short interest and volume change

    had 3.0M shares sold short in the 15 Apr 2025 report, 1.6× the same report last year.

    Same report last year: 1.9M; its normal report is 2.0M.

    See the evidence
    This period
    3.0M (the 15 Apr 2025 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    166K
    How far from its usual level
    +4.4
    Same report last year
    1.9M
    History used
    2,664 days
    2024-04-15: 1.9M2024-04-30: 1.9M2024-05-15: 1.7M2024-05-31: 2.1M2024-06-14: 1.9M2024-06-28: 1.8M2024-07-15: 1.8M2024-07-31: 1.8M2024-08-15: 1.6M2024-08-30: 1.5M2024-09-13: 1.9M2024-09-30: 2.0M2024-10-15: 2.1M2024-10-31: 1.9M2024-11-15: 1.9M2024-11-29: 2.2M2024-12-13: 2.1M2024-12-31: 2.3M2025-01-15: 2.2M2025-01-31: 2.0M2025-02-14: 2.3M2025-02-28: 2.9M2025-03-14: 3.3M2025-03-31: 2.7M2025-04-15: 3.0M
    the 15 Apr 2025 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  37. 26 Mar 2025Short interest and volume change

    had 3.3M shares sold short in the 14 Mar 2025 report, 2.1× the same report last year.

    Same report last year: 1.6M; its normal report is 1.9M.

    See the evidence
    This period
    3.3M (the 14 Mar 2025 report)
    Normal report (median of 24 earlier)
    1.9M
    Typical spread (median absolute deviation)
    186K
    How far from its usual level
    +5.1
    Same report last year
    1.6M
    History used
    2,632 days
    2024-03-15: 1.6M2024-03-28: 1.6M2024-04-15: 1.9M2024-04-30: 1.9M2024-05-15: 1.7M2024-05-31: 2.1M2024-06-14: 1.9M2024-06-28: 1.8M2024-07-15: 1.8M2024-07-31: 1.8M2024-08-15: 1.6M2024-08-30: 1.5M2024-09-13: 1.9M2024-09-30: 2.0M2024-10-15: 2.1M2024-10-31: 1.9M2024-11-15: 1.9M2024-11-29: 2.2M2024-12-13: 2.1M2024-12-31: 2.3M2025-01-15: 2.2M2025-01-31: 2.0M2025-02-14: 2.3M2025-02-28: 2.9M2025-03-14: 3.3M
    the 14 Mar 2025 report24 earlier reportsnormal: 1.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  38. 19 Mar 2025Government contracts record

    CHARLES RIVER LABORATORIES, INC.: new Department of Health and Human Services contract 75N98025F00008 ($3.3M) (dated 13 Mar 2025)

  39. 12 Mar 2025Short interest and volume change

    had 2.9M shares sold short in the 28 Feb 2025 report, 1.7× the same report last year.

    Same report last year: 1.8M; its normal report is 1.9M.

    See the evidence
    This period
    2.9M (the 28 Feb 2025 report)
    Normal report (median of 24 earlier)
    1.9M
    Typical spread (median absolute deviation)
    150K
    How far from its usual level
    +4.7
    Same report last year
    1.8M
    History used
    2,618 days
    2024-02-29: 1.8M2024-03-15: 1.6M2024-03-28: 1.6M2024-04-15: 1.9M2024-04-30: 1.9M2024-05-15: 1.7M2024-05-31: 2.1M2024-06-14: 1.9M2024-06-28: 1.8M2024-07-15: 1.8M2024-07-31: 1.8M2024-08-15: 1.6M2024-08-30: 1.5M2024-09-13: 1.9M2024-09-30: 2.0M2024-10-15: 2.1M2024-10-31: 1.9M2024-11-15: 1.9M2024-11-29: 2.2M2024-12-13: 2.1M2024-12-31: 2.3M2025-01-15: 2.2M2025-01-31: 2.0M2025-02-14: 2.3M2025-02-28: 2.9M
    the 28 Feb 2025 report24 earlier reportsnormal: 1.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  40. 12 Mar 2025Government contracts record

    CHARLES RIVER LABORATORIES, INC.: new Department of Health and Human Services contract 75N95025F00001 ($3.0M) (dated 6 Mar 2025)

Showing the newest 40 of 166 entries; narrow the window or the kind of data to see older ones.

Not listed: 424 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001100682
Ticker
CRL
Domain
criver.com
Employer name
Charles River Laboratories, Inc. (1 unverified)
Hq location
MA|WILMINGTON|01887 (1 unverified)
Lobbying client
charles river laboratories, charles river laboratories international
Name
CHARLES RIVER LABORATORIES HOLDINGS INC, Charles River Laboratories International, Inc.
Uei
F2KENCWX3M63, TR8RLF6C9H15
Wikidata
Q5082076
Wikipedia
Charles River Laboratories
  • DOL H-1B labor condition applications and PERM certifications864 data points1 Oct 2019 to 28 Sep 2026
  • Federal lobbying disclosures (LDA)11 records, 168 data points31 Dec 2006 to 30 Sep 2026
  • SEC Form 13F institutional holdings1 record, 481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)143 records8 Jan 2016 to 4 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1167 data points29 Dec 2007 to 24 Oct 2026
  • SEC Form 4 insider transactions323 records, 684 data points3 Feb 2016 to 26 Oct 2026
  • FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards87 records, 7000 data points1 Oct 2007 to 5 Nov 2026
  • WARN layoff notices (state labor agencies)3 records, 9 data points4 Nov 2024 to 10 Nov 2026
  • Wikipedia pageviews2882 data points1 Jan 2019 to 21 Nov 2026